The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $34.34

Today's change0.00 0.00%
Updated August 4 4:00 PM EDT. Delayed by at least 15 minutes.
 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $34.34

Today's change0.00 0.00%
Updated August 4 4:00 PM EDT. Delayed by at least 15 minutes.

AstraZeneca PLC closed at (U.S.)$34.34.

Over the last five days, shares have gained 4.66%, but are currently unchanged over the last year to date. Shares have underperformed the S&P 500 by 14.76% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $34.34
  • High--
  • Low--
  • Bid / Ask(U.S.) $34.29 / (U.S.) $34.31
  • YTD % change-2.42%
  • Volume0
  • Average volume (10-day)1,967,460
  • Average volume (1-month)2,328,974
  • Average volume (3-month)2,693,493
  • 52-week range(U.S.) $31.61 to (U.S.) $38.12
  • Beta0.71
  • Trailing P/E73.66×
  • P/E 1 year forward16.20×
  • Forward PEG6.61×
  • Indicated annual dividend(U.S.) $1.40
  • Dividend yield4.08%
  • Trailing EPS(U.S.) $0.47
Updated August 4 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+4.61%

Based on its net profit margin of 4.61%, AstraZeneca PLC is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue6,3076,0576,6836,542
Total other revenue--------
Total revenue6,3076,0576,6836,542
Gross profit5,2984,8315,0515,184
Total cost of revenue1,0091,2261,6321,358
Total operating expense5,3845,1247,0326,001
Selling / general / administrative2,5852,4583,0662,767
Research & development1,3561,2801,3601,275
Depreciation / amortization376265306342
Interest expense (income), net operating--------
Unusual expense (income)3433211,027515
Other operating expenses, total-285-426-359-256
Operating income923933-349541
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax658678-580322
Income after tax696552-321253
Income tax, total-38126-25969
Net income697550-321254
Total adjustments to net income--------
Net income before extra. items697550-321254
Minority interest1-201
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items697550-321254
Inc. avail. to common incl. extra. items697550-321254
Diluted net income697550-321254
Dilution adjustment--00--
Diluted weighted average shares1,2651,2651,2621,264
Diluted EPS excluding extraordinary itemsvalue per share0.550.43-0.250.20
Dividends per sharevalue per share0.950.000.900.00
Diluted normalized EPSvalue per share0.830.700.820.78